GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Bloomios Inc (OTCPK:BLMS) » Definitions » Altman Z2-Score

Bloomios (Bloomios) Altman Z2-Score : -326.95 (As of Jun. 16, 2024)


View and export this data going back to 2003. Start your Free Trial

What is Bloomios Altman Z2-Score?

Altman Z2-Score, also known as Z"-Score, is used to predict the likelihood that a non-manufacturing company (excluding property/financial company) will face bankruptcy within a two-year period.

Warning Sign:

Bloomios has a Altman Z2-Score of -326.95, indicating it is in Distress Zones. This implies bankrupcy possibility in the next two years.

The zones of discrimination were as such:

When Altman Z2-Score <= 1.1, it is in Distress Zones.
When Altman Z2-Score >= 2.6, it is in Safe Zones.
When Altman Z2-Score is between 1.1 and 2.6, it is in Grey Zones.

The historical rank and industry rank for Bloomios's Altman Z2-Score or its related term are showing as below:

BLMS' s Altman Z2-Score Range Over the Past 10 Years
Min: -326.95   Med: -14.42   Max: -12.15
Current: -326.95

During the past 10 years, Bloomios's highest Altman Z2-Score was -12.15. The lowest was -326.95. And the median was -14.42.


Bloomios Altman Z2-Score Historical Data

The historical data trend for Bloomios's Altman Z2-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bloomios Altman Z2-Score Chart

Bloomios Annual Data
Trend Jun02 Jun03 Jun04 Jan05 Jan06 Jan07 Jan19 Jan20 Dec21 Dec22
Altman Z2-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1,324.95 - - -14.64 -12.26

Bloomios Quarterly Data
Oct18 Jan19 Apr19 Jul19 Oct19 Jan20 Apr20 Jul20 Oct20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Altman Z2-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -36.13 -12.26 -13.27 -14.42 -326.95

Competitive Comparison of Bloomios's Altman Z2-Score

For the Drug Manufacturers - Specialty & Generic subindustry, Bloomios's Altman Z2-Score, along with its competitors' market caps and Altman Z2-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Bloomios's Altman Z2-Score Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Bloomios's Altman Z2-Score distribution charts can be found below:

* The bar in red indicates where Bloomios's Altman Z2-Score falls into.



Bloomios Altman Z2-Score Calculation

Altman Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.

Z2-Score, also known as Z"-Score is the Z-Score for non-manufacturing companies excluding property/financial companies.

Bloomios's Altman Z2-Score for today is calculated with this formula:

Z=6.56*X1+3.26*X2+6.72*X3+1.05*X4_2
=6.56*-16.9679+3.26*-26.4855+6.72*-19.0533+1.05*-1.1967
=-326.95

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency. GuruFocus does not calculate Altman Z2-Score when X4_2 value is 0.

Trailing Twelve Months (TTM) ended in Sep. 2023:
Total Assets was $1.93 Mil.
Total Current Assets was $0.35 Mil.
Total Current Liabilities was $33.13 Mil.
Retained Earnings was $-51.17 Mil.
Pre-Tax Income was -26.033 + -2.292 + -2.735 + -8.549 = $-39.61 Mil.
Interest Expense was -0.36 + -0.921 + -1.076 + -0.441 = $-2.80 Mil.
Total Liabilities was $33.40 Mil.

* Note that for stock reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data.

X1=Working Capital/Total Assets
=(Total Current Assets - Total Current Liabilities)/Total Assets
=(0.346 - 33.128)/1.932
=-16.9679

X2=Retained Earnings/Total Assets
=-51.17/1.932
=-26.4855

X3=Earnings Before Interest and Taxes/Total Assets
=(Pre-Tax Income - Interest Expense)/Total Assets
=(-39.609 - -2.798)/1.932
=-19.0533

X4_2=Net Worth/Total Liabilities
=(Total Stockholders Equity - Preferred Stock)/Total Liabilities
=(-31.465 - 8.5)/33.397
=-1.1967

The zones of discrimination were as such:

Distress Zones - 1.1 < Grey Zones < 2.6 - Safe Zones

Bloomios has a Altman Z2-Score of -326.95 indicating it is in Distress Zones.


Bloomios  (OTCPK:BLMS) Altman Z2-Score Explanation

The original Z-Score model was based on publicly traded manufacturing companies while the Z2-Score, also known as Z"-score can be used for any type of company excluding property/financial companies. Both Z-Score and Z2-Score describes the financial health of a company, and its likelihood of financial distress.

X1: The Working Capital/Total Assets (WC/TA) ratio is a measure of the net liquid assets of the firm relative to the total capitalization. Working capital is defined as the difference between current assets and current liabilities. Ordinarily, a firm experiencing consistent operating losses will have shrinking current assets in relation to total assets. Altman found this one proved to be the most valuable liquidity ratio comparing with the current ratio and the quick ratio. This is however the least significant of the five factors.

X2: Retained Earnings/Total Assets: the RE/TA ratio measures the leverage of a firm. Retained earnings is the account which reports the total amount of reinvested earnings and/or losses of a firm over its entire life. Those firms with high RE, relative to TA, have financed their assets through retention of profits and have not utilized as much debt.

X3, Earnings Before Interest and Taxes/Total Assets (EBIT/TA): This ratio is a measure of the true productivity of the firm's assets, independent of any tax or leverage factors. Since a firm's ultimate existence is based on the earning power of its assets, this ratio appears to be particularly appropriate for studies dealing with corporate failure. This ratio continually outperforms other profitability measures, including cash flow.

X4_2, Net Worth (Total Stockholders Equity - Preferred Stock)/Total Liabilities (NW/TL): it compares a company’s stock net worth with its total liabilities and can be used to assess the extent of its reliance on debt.

Read more about Altman Z2-Score, the original research on Z-Score and the additional research on Z2-Score.


Be Aware

Altman Z2-Score does not apply to financial companies.


Bloomios Altman Z2-Score Related Terms

Thank you for viewing the detailed overview of Bloomios's Altman Z2-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Bloomios (Bloomios) Business Description

Traded in Other Exchanges
N/A
Address
701 Anacapa Street, Suite C, Santa Barbara, CA, USA, 93101
Bloomios Inc manufactures, markets, and distributes U.S. hemp-derived supplements and cosmetic products through wholesale distribution channels in the United States of America. It offers its private-label and white-label customers large collections of customizable hemp products that include over 80 products across 7 categories in addition to custom formulation and manufacturing services. Its product categories include edibles, tinctures, oils, salves, capsules, balms, lotions, creams, beverages, and pet treats.
Executives
Douglas S Rohrer officer: Chief Business Officer 701 ANACAPA, SUITE C, SANTA BARBARA CA 93101
Emc2 Capital Llc 10 percent owner 201 W MONTECITO STREET, SANTA BARBARA CA 93101
Barrett Evans director, 10 percent owner, officer: Pres, Chief Strategy Officer
Aline Hayuta Elkayam 10 percent owner 104 CHELSEA PLACE, ORMOND BEACH FL 32174
Bibi Daprile 10 percent owner 12 WINDING CREEK WAY, ORMOND BEACH FL 32174
Agpl Acquisition, Inc 10 percent owner 201 W MONTECITO ST., SANTA BARBARA CA 93101
Mammoth Crest Capital Llc 10 percent owner 1712 PIONEER AVE, SUITE 558, CHEYENNE WY 82001
Michael Hill director, 10 percent owner, officer: Chief Executive Officer 201 WEST MONTECITO STREET, SANTA BARBARA CA 93101
Bryan Glass director, 10 percent owner, officer: President and Director 20 WEST PARK AVENUE, SUITE 207, LONG BEACH NY 11561
Douglas Boyd director, officer: Chairman of the Board 8101 TIARA COVE CIR, LAS VEGAS NV 89128
Peter A Hogendoorn director, officer: President & CEO 13288 AMBLE GREEN PLACE, SURREY A1 V4A 6P5
Harold C Moll director, 10 percent owner
Van Laare Derek R officer: Secretary 6119 GORDON AVENUE, BURNABY A1 V5E 3M2
Carlo Civelli other: former director/officer/owner 111 SOMERSET ROAD, TRIPLE ONE SOMERSET 06-06, SINGAPORE U0 238164
Logan Anderson director, officer: President & Treasurer 15 HILL CRESCENT, PEMBROKE BERMUDA D8 00000